Early Disease Activity or Clinical Response as Predictors of Long‐Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis

OBJECTIVE: Early identification of patients unlikely to achieve good long‐term disease control with anti–tumor necrosis factor therapy in axial spondyloarthritis (SpA) and psoriatic arthritis (PsA) is important for physicians following treat‐to‐target recommendations. Here we assess associations bet...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Arthritis Care Res (Hoboken)
Main Authors: van der Heijde, D., Deodhar, A., Fleischmann, R., Mease, P. J., Rudwaleit, M., Nurminen, T., Davies, O.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2017
Assuntos:
Spondyloarthritis
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5518306/
https://ncbi.nlm.nih.gov/pubmed/27696727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acr.23092
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares